| Anticoagulation for cardioversion of atrial arrhythmias. | |
| | |
MedLine Citation:
|
PMID: 9597402 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We would advocate 3 weeks of anticoagulation prior to, and 4 weeks post-cardioversion (either electrical or chemical) for patients in chronic atrial fibrillation or flutter. In selected cases it seems reasonable to use transoesophageal echocardiography to exclude preformed thrombus and negate the need for 3 weeks of prior anticoagulation. For patients presenting acutely with atrial fibrillation or flutter we suggest anticoagulating with heparin immediately on presentation and for those who do not spontaneously revert to sinus rhythm, using transoesophageal echocardiography to exclude atrial thrombi prior to cardioversion. Oral anticoagulation should be continued for 4 weeks post-procedure. If transoesophageal echocardiography is not readily available an alternative strategy would be to anticoagulate the patient for 3 weeks and thereafter readmit them for elective cardioversion, continuing the anticoagulation for a further 4 weeks after the procedure. |
| | |
Authors:
|
J Mayet; R S More; G C Sutton |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: European heart journal Volume: 19 ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 1998 Apr |
Date Detail:
|
Created Date: 1998-07-22 Completed Date: 1998-07-22 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 548-52 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Hillingdon Hospital, London, U.K. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Anticoagulants / administration & dosage* Atrial Fibrillation / drug therapy*, therapy Chronic Disease Electric Countershock* / adverse effects Female Humans Male Randomized Controlled Trials as Topic Thromboembolism / etiology, prevention & control* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants |
| Comments/Corrections | |
Comment In:
|
Eur Heart J. 1999 Feb;20(4):317
[PMID:
10099928
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occ...
Next Document: 5993 survivors of suspected myocardial infarction. 10 year incidence of later myocardial infarction ...